News & Events
2009
-
December 24, 2009Kowa Company, Ltd. Opens Collaborative Cardiovascular Research Center with Brigham and Women's Hospital
-
August 3, 2009FDA Approves LIVALOR for Primary Hypercholesterolemia and Combined Dyslipidemia
FDA Approves LIVALOR for Primary Hypercholesterolemia and Combined Dyslipidemia.
Montgomery, AL and Morrisville, NC August 03, 2009 - Kowa Research Institute (KRI)based in Morrisville, NC and Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. Food and Drug Administration (FDA) has approved LIVALOR (pitavastatin), a potent HMG-CoA reductase inhibitor (statin), for the primary treatment of hypercholesterolemia and combined dyslipidemia.